{
    "medicine_id": "37a1638044bd71fa8e6b7e3a6fbd4f56ae661905",
    "platform_id": "DB05974",
    "metadata": {
        "name": "Besponsa 0 25 mg 1mL Injection powder lyophilized for solution",
        "composition": "0 25 mg 1mL Transcrocetinate",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in cancer tumors unspecified hemorrhage hypoxia respiratory failure and strokes",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "NA",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Transcrocetinate"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Transcrocetinate"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Transcrocetinate"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Transcrocetinate"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}